Browsing Tag
NLC Health Ventures
1 post
Thalia Therapeutics (AIM: THAT) shares jump 17% as Sanmirna deal adds Phase 1 AML asset
Thalia Therapeutics has agreed to acquire Sanmirna Therapeutics and its Phase 1 acute myeloid leukaemia drug miRisten, while raising ÂŁ2.75 million to fund clinical data expected in 2027.